Geron (STU:GON) Accounts Payable : €9.19 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Geron Accounts Payable?

Geron's Accounts Payable for the quarter that ended in Mar. 2024 was €9.19 Mil.

Geron's quarterly Accounts Payable declined from Sep. 2023 (€12.82 Mil) to Dec. 2023 (€5.65 Mil) but then increased from Dec. 2023 (€5.65 Mil) to Mar. 2024 (€9.19 Mil).

Geron's annual Accounts Payable increased from Dec. 2021 (€5.92 Mil) to Dec. 2022 (€9.62 Mil) but then declined from Dec. 2022 (€9.62 Mil) to Dec. 2023 (€5.65 Mil).

Geron Accounts Payable Historical Data

The historical data trend for Geron's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Accounts Payable Chart

Geron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

1.06

5.69

5.92

9.62

5.65

Geron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															3.16	7.08	12.82	5.65	9.19

Geron Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Geron Accounts Payable Related Terms

Thank you for viewing the detailed overview of Geron's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron (STU:GON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

GERN:USA

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Geron (STU:GON) Headlines

No Headlines